This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Erythema multiforme-like bullous pemphigoid following COVID-19 mRNA vaccine (preprint)
authorea preprints; 2022.
Preprint
in English
| PREPRINT-AUTHOREA PREPRINTS | ID: ppzbmed-10.22541.au.166548291.16155268.v1
ABSTRACT
Cases of bullous pemphigoid following Covid-19 vaccines have been recently reported. We describe herein an atypical case of acral bullous pemphigoid after Pfizer BionTech vaccine. Clinicians should be aware of this reaction and encourage full vaccination as the disease displays a rapid improvement treatment.
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-AUTHOREA PREPRINTS
Main subject:
Pemphigoid, Bullous
/
COVID-19
Language:
English
Year:
2022
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS